Vericiguat: A New Hope for Heart Failure Patients

Figure 1

(a) The correlation between the ejection fraction and the cardiac function. (b) Mechanisms of action of vericiguat. Red arrows: heart failure is characterized by endothelial dysfunction, oxidative stress, and inflammation which leads to reduced nitric oxide (NO) bioavailability and inadequate activation of intracellular soluble guanylate cyclase (sGC). The resulting cyclic guanosine monophosphate (cGMP) deficiency is linked to cardiac and vascular dysfunction. Green arrows: vericiguat directly and indirectly increases the available amount of cGMP leading to various beneficial effects.

(a)

(b)